Novo Nordisk A/S Common Stock (NVO)

This might be a wonderful entry point for long-term investors.

The drugmaker's recent dip could also be a buying opportunity.

Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath.

It seems to be holding off on price adjustments demanded by President Trump.

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.

Eli Lilly's pricing strategy for GLP-1 drugs is expected to have minimal margin impact, with BofA reaffirming a $900 price target.

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other cardiometabolic diseases.

These stocks are all down more than 30% this year and could prove to be bargain buys for long-term investors.

Eli Lilly will raise Mounjaro's UK price by 170% in September while launching its Kwikpen injector in India, intensifying competition with Novo Nordisk in the global obesity drug market.

Healthcare stocks are underperforming this year due to unfavorable government policy.

Bullishness slowly seems to be coming back to the beleaguered drugmaker.

The GLP-1 weight loss wars have gone global.

Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.

Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting treatment options despite competition from Eli Lilly.

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

Novo Nordisk filed more Wegovy lawsuits against smaller U.S. firms, as the FDA sets a compounding deadline. Hims & Hers was not named in the new cases.

Investors have a tough choice between these two excellent companies.

A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and pharmacy-based services by summer 2026.

NOVO-NORDISK (NVO) is a top value stock with strong fundamentals, undervalued metrics, high profitability, and steady growth in diabetes & obesity care markets.

News from a competitor is increasing enthusiasm for Novo Nordisk stock.

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to district court for further proceedings.

They all offer great value right now.

These two underappreciated dividend payers offer above-average yields and relatively rapid payout growth.